Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials
Authors' conclusion
Beneficial CV and renal effects of SGLT2i are similar against the placebo regardless of background DPP4i therapy.
Study context
- Population
- People with T2D in cardiovascular (CV) outcome trials of SGLT2i vs placebo; PubMed and Embase searched until January 31, 2023CV outcome trials (CVOTs) vs placebo
- Comparison
- SGLT2i with vs without background DPP-4i therapy, each vs placebo
- Outcome
- Heterogeneity of SGLT2i effect vs placebo by background DPP4i therapy
Methodological detailstrial-level, random-effects, inverse variance-weighted
- Trial-level
- Random-effects
- Inverse variance-weighted
Pooled result
As reported in the abstract
- Beneficial CV and renal outcomes with SGLT2i vs placebo were similar with or without background DPP4i therapy
- Summary estimates for 3-point MACE, hHF and renal outcomes stronger with SGLT2i alone; for CV death or hHF larger with SGLT2i + background DPP4i
- SGLT2i + DPP4i vs SGLT2i alone: P for heterogeneity = 0.71
- SGLT2i + DPP4i vs SGLT2i alone: P for heterogeneity = 0.07
- SGLT2i + DPP4i vs SGLT2i alone: P for heterogeneity = 0.87
- SGLT2i + DPP4i vs SGLT2i alone: P for heterogeneity = 0.72
- SGLT2i + DPP4i vs SGLT2i alone: P for heterogeneity = 0.25
Original publication
Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials. Endocr Pract. Published 8 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →